1 Zülch K.J. Pathologische Anatomie der raumbeengenden intrakraniellen Prozesse. Handbuch der Neurochirurgie, 3. Band, Hrsg. H.Olivecrona und W.Tönnis:Springer Berlin;1956.
2 Kneifel S, Cordier D, Good S, Ionescu MCS, Ghaffari A, Hofer S, et al. Local Targeting of Malignant Gliomas by the Diffusible Peptidic Vector 1,4,7,10-Tetraazacyclododecane-1-Glutaric Acid-4,7,10-Triacetic Acid-Substance P. Clin Cancer Res 2006;12(12): 3843–50.
3 Cordier D, Forrer F, Kneifel S, Sailer M, Mariani L, Mäcke H, et al. Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGA-substance P-results from a phase I study. J Neurooncol. 2010;100(1):129–36.
4 Cordier D, Forrer F, Bruchertseifer F, Morgenstern A, Apostolidis C, Good S, et al. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTAGA-substance P: a pilot trial. Eur J Nucl Med Mol Imaging. 2010;37(7):1335–44.
5 Cordier D, Krolicki L, Morgenstern A, Merlo A. Targeted Radiolabeled Compounds in Glioma Therapy. Semin Nucl Med. 2016;46(3):243–9.
6 Kneifel S, Bernhardt P, Uusijärvi H, Good S, Plasswilm L, Buitrago-Téllez C, et al. Individual Voxelwise Dosimetry of Targeted 90Y-labelled Substance P Radiotherapy for Malignant Gliomas. Eur J Nucl Med Mol Imaging 2007; 34(9):1388–95.
7 Linz U. Commentary on Lancet Oncol. 2009;10:459–66. Cancer. 2010;116(8):1844–6.